(Photo: economictimes.com)

AstraZeneca reveals positive trial results

The coronavirus (COVID-19) pandemic has created a competition for the first COVID-19 vaccine between pharmaceutical companies worldwide and it seems that AstraZeneca is getting close to human trails. Oxford is one of the leading authorities in the world in creating vaccines and has worked on the COVID-19 vaccine since January.

After months of hard work, Oxford has reached the first milestone in human trials for the experimental AstraZeneca COVID-19 vaccine, ChAdOx1 nCoV-19 (ADZ1222). According to a report in the Lancet, phase I results of the ADZ1222 vaccine trial produces a strong immune response in humans and hasn’t caused unexpected side-effects.

Oxford’s Covid-19 vaccine produces a good immune response, reveals new study.
Teams at @VaccineTrials and @OxfordVacGroup have found there were no safety concerns, and the vaccine stimulated strong immune responses: https://t.co/krqRzXMh7B pic.twitter.com/Svd3MhCXWZ

— University of Oxford (@UniofOxford) July 20, 2020

The next part of the trial is to see whether the ADZ1222 vaccine immune response protects against COVID-19 and how different age groups react to the new vaccine. These trials are already in the process thanks to the help of thousands of volunteers and AstraZeneca is working fast to ensure offering large quantities when available to the public.

Researchers of the AstraZeneca vaccine released reports showing the ADZ1222 vaccine produces killer T-cells and antibodies to combat infection within two months. Phase 1 of the ADZ1222 trials had more than 1,000 participants ranging in ages from 18 to 55.

Researchers say ADZ1222 neutralizes antibodies that are believed to gain protection against the virus and the T-cell response didn’t increase with the second dose of the vaccine. These test results are consistent with similar vaccines with researchers focusing on how the immune system finds and attacks pathogens-antibody and T cell responses.

There are at least 100 COVID-19 vaccines being developed all around the world and at least 23 of the vaccines are already going through human trials. The biotech firm, Moderna, released promising data on its potential COVID-19 vaccine trial with subjects displaying a “robust” immune response.

Oxford University scientists say experimental coronavirus vaccine has been shown in an early trial to prompt an immune response in hundreds who got the shot. Phase 3 trials are needed to confirm whether the vaccine effectively protects against infection. https://t.co/rTaq9qZrLf

— CBC News Alerts (@CBCAlerts) July 20, 2020

The pharmaceutical giant Pfizer is working with the German drugmaker BioNTech revealed positive test results for its early-stage human trial for its COVID-19 vaccine. The preliminary data shows that this vaccine produced neutralizing antibodies after receiving the 10 or 30 microgram doses after 28 days.

Though the competition is still in trial phases, AstraZeneca is getting ready for the ADZ1222 production and is working with the Coalition for Epidemic Preparedness Innovations.